Non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Oh, Hyunwoo | - |
dc.contributor.author | Jun, Dae Won | - |
dc.contributor.author | Saeed, Waqar K. | - |
dc.contributor.author | Nguyen, Mindie H. | - |
dc.date.accessioned | 2021-08-02T16:28:02Z | - |
dc.date.available | 2021-08-02T16:28:02Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2016-09 | - |
dc.identifier.issn | 2287-2728 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/22210 | - |
dc.description.abstract | The prevalence of non-alcoholic fatty liver disease (NAFLD) is estimated to be 25-30% of the population, and is the most common cause of elevated liver enzymes in Korea. NAFLD is a "hot potato" for pharmaceutical companies. Many clinical trials are underway to develop a first-in-class drug to treat NAFLD. However, there are several challenging issues regarding the diagnosis of NAFLD. Currently, liver biopsy is the gold standard method for the diagnosis of NAFLD and steatohepatitis. Ideally, globally recognized standards for histological diagnosis and methods to optimize observer agreement on biopsy interpretation should be developed. Liver biopsy is the best method rather than a perfect one. Recently, multi-parametric magnetic resonance imagery can estimate the amount of intrahepatic fat successfully and is widely used in clinical trials. But no diagnostic method can discriminate between steatohepatitis and simple steatosis. The other unresolved issue in regard to NAFLD is the absence of satisfactory treatment options. Vitamin E and obeticholic acid have shown protective effects in randomized controlled trials, but this drug has not been approved for use in Korea. This study will provide a description of diagnostic methods and treatments that are currently recommended for NAFLD. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | KOREAN ASSOC STUDY LIVER | - |
dc.title | Non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Jun, Dae Won | - |
dc.identifier.doi | 10.3350/cmh.2016.0049 | - |
dc.identifier.scopusid | 2-s2.0-85014810867 | - |
dc.identifier.bibliographicCitation | CLINICAL AND MOLECULAR HEPATOLOGY, v.22, no.3, pp.327 - 335 | - |
dc.relation.isPartOf | CLINICAL AND MOLECULAR HEPATOLOGY | - |
dc.citation.title | CLINICAL AND MOLECULAR HEPATOLOGY | - |
dc.citation.volume | 22 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 327 | - |
dc.citation.endPage | 335 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | CLINICAL SCORING SYSTEM | - |
dc.subject.keywordPlus | LIFE-STYLE INTERVENTION | - |
dc.subject.keywordPlus | MORBIDLY OBESE-PATIENTS | - |
dc.subject.keywordPlus | HEPATIC STEATOSIS | - |
dc.subject.keywordPlus | STEATOHEPATITIS NASH | - |
dc.subject.keywordPlus | PLASMA CYTOKERATIN-18 | - |
dc.subject.keywordPlus | HISTOLOGICAL LESIONS | - |
dc.subject.keywordPlus | RANDOMIZED-TRIAL | - |
dc.subject.keywordPlus | BIOMARKER PANEL | - |
dc.subject.keywordPlus | FIBROSIS | - |
dc.subject.keywordAuthor | Non-alcoholic fatty liver | - |
dc.subject.keywordAuthor | Diagnosis | - |
dc.subject.keywordAuthor | Treatment | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.